Construction and immunological evaluation of recombinant adenovirus vaccines of new novel NADC34-PRRSV strains in pigs
2024

New Vaccines for PRRSV in Pigs

Sample size: 35 publication Evidence: high

Author Information

Author(s): Xie Chang-zhan, Zhang Ping, Wang Zheng, Tao Yi-mo, Cui Zhuo-dong, Nan Fu-long, Zhang Fu-chao, Ren Yun-xin, Zhang He, Lu Hui-jun

Primary Institution: Chinese Academy of Agricultural Sciences

Hypothesis

Can recombinant adenovirus vaccines effectively protect pigs against the newly emerged NADC34-like PRRSV strain?

Conclusion

The recombinant adenovirus vaccines provide good protective immunity and induce both humoral and cellular immune responses in pigs.

Supporting Evidence

  • Vaccinated animals showed significantly higher levels of IFN-γ and IL-4 cytokines compared to control groups.
  • Immunized pigs did not exhibit clinical symptoms after being challenged with the virus.
  • The recombinant vaccines reduced viremia and showed lower viral loads in tissues compared to control groups.

Takeaway

Scientists created new vaccines to help protect pigs from a virus that makes them sick, and the vaccines worked well.

Methodology

The study involved constructing recombinant adenovirus vaccines and testing their immunogenicity in piglets by measuring specific antibodies and cytokines after vaccination.

Participant Demographics

Weaned piglets aged 4-5 weeks.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fvets.2024.1503526

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication